Original Source(s)
Related Content
Extended antiviral therapy may not improve long COVID
Nirmatrelvir–ritonavir for up to 25 days failed to improve cognitive, autonomic, or exercise symptoms compared with placebo in a phase 2 trial.
September 4, 2026
-
4 min
FDA approves hepcidin mimetic for PV
Phase 3 VERIFY results showed a 77% clinical response rate during weeks 20 to 32.
August 31, 2026
-
3 min
36 genes may reshape OCD, tic genetics
Whole-exome sequencing identifies large-effect risk genes across obsessive-compulsive and chronic tic disorders, with most supported by both conditions.
September 2, 2026
-
3 min
